Estrogen component of OCs.
Dialogues Contracept
; 5(4): 1-6, 1997.
Article
en En
| MEDLINE
| ID: mdl-12293158
PIP: Dramatic reductions in both the estrogen and progestin doses of combined oral contraceptives (OCs) have created a need for regular reassessment of safety and side effect issues. The development of OCs with estrogen doses of less than 50 mcg has resulted in fewer adverse hematologic and cardiovascular effects while retaining the contraceptive and noncontraceptive benefits of these agents. This article, intended to help US clinicians make sound OC prescribing recommendations, reviews the effect of the estrogen component of available OCs on adverse cardiovascular effects (venous thrombosis and embolism, myocardial infarction, and thrombotic and hemorrhagic stroke), breast cancer risk, and menstrual cycle control. Although a review of the available research evidence suggests that OC use is associated with a three-fold increase in the risk of venous thromboembolism, this is half of the risk associated with pregnancy. OCs with more than 35 mcg of estrogen should be reserved for women with specific conditions (e.g., concomitant use of hepatic enzyme-inducing drugs). From the perspective of safety, compliance, and noncontraceptive health benefits, OCs containing 30-35 mcg of estrogen represent a more prudent choice for the majority of women than do 20-mcg-dose OCs due, in large part, to the poor cycle control associated with the lowest-dose OCs.^ieng
Palabras clave
Americas; Biology; Breast Cancer; Cancer; Contraception; Contraceptive Methods--administraction and dosage; Contraceptive Methods--side effects; Developed Countries; Diseases; Embolism; Endocrine System; Estrogens--administraction and dosage; Estrogens--side effects; Family Planning; Heart Diseases; Hormones; Menstruation Disorders; Myocardial Infarction; Neoplasms; North America; Northern America; Oral Contraceptives--administraction and dosage; Oral Contraceptives--side effects; Physiology; Risk Factors; Thromboembolism; United States; Vascular Diseases
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tromboembolia
/
Neoplasias de la Mama
/
Factores de Riesgo
/
Anticonceptivos Orales
/
Estrógenos
/
Trastornos de la Menstruación
/
Infarto del Miocardio
Tipo de estudio:
Etiology_studies
/
Guideline
/
Risk_factors_studies
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Dialogues Contracept
Año:
1997
Tipo del documento:
Article
Pais de publicación:
Estados Unidos